Vildagliptin

Vildagliptin is an oral antidiabetic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitors class of drugs. It is used in the management of type 2 diabetes mellitus, a chronic condition characterized by high levels of glucose in the blood due to insulin resistance or deficiency. Vildagliptin works by increasing the levels of incretin hormones in the body, which in turn increases insulin release in response to meals and decreases the amount of glucose produced by the liver.

Mechanism of Action[edit | edit source]

Vildagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the inactivation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released by the intestine in response to food intake and have a significant role in the regulation of glucose metabolism. By inhibiting DPP-4, vildagliptin increases the levels of active incretin hormones, which enhances glucose-dependent insulin secretion from the pancreatic beta cells and suppresses glucagon release from the alpha cells. This dual action helps in reducing fasting and postprandial blood glucose levels.

Clinical Use[edit | edit source]

Vildagliptin is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control in adults. It can be used alone or in combination with other antidiabetic medications such as metformin, a thiazolidinedione, a sulfonylurea, or insulin, when diet and exercise plus the single agent do not provide adequate glycemic control.

Side Effects[edit | edit source]

The most common side effects associated with vildagliptin include headache, nasopharyngitis, and upper respiratory tract infections. It has a relatively low risk of hypoglycemia when used alone but this risk may increase when used in combination with a sulfonylurea or insulin. Other less common side effects may include dizziness, joint pain, and edema. Pancreatitis has been reported but its incidence is rare.

Contraindications[edit | edit source]

Vildagliptin is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients. It is also contraindicated in patients with severe renal impairment, hepatic disease, or history of pancreatitis.

Pharmacokinetics[edit | edit source]

Vildagliptin is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 1 to 2 hours. It is primarily metabolized by hydrolysis, followed by renal excretion. The half-life of vildagliptin is approximately 2 hours, and it is excreted mainly in the urine.

Regulatory Status[edit | edit source]

Vildagliptin has been approved for use in numerous countries around the world for the treatment of type 2 diabetes. Its approval and availability vary by country, with some countries approving it for use as monotherapy or in combination with other antidiabetic agents.